April19 Discovery

We use next-gen machine learning to find novel psychedelic drug compounds. Classical (first-generation) psychedelics have never been optimized to treat any disease and so we aim to design compounds with the optimal risk-benefit ratio in various indications. Beyond mental health, we focus on neurodegeneration and neural injuries, increasing brain longevity and extending human mental healthspan.
Social Link - Linkedin: http://www. linkedin.com/company /april19ai
Employee Count: 3
Keywords: ai